Univest
Univest
  • Markets

Balaxi Pharmaceuticals Ltd. Hits Upper Circuit on NSE, 18 November 2026

  • November 18, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Balaxi Pharmaceuticals upper circuit today on NSE

On 18 November 2026, Balaxi Pharmaceuticals Ltd. (BALAXI) hit the upper circuit on NSE at Rs 31.76, a 19.98% positive move from the previous close of Rs 26.47. The company’s market cap stood at Rs 146.13 crore. The upper circuit price for the session was Rs 31.76.

The Balaxi Pharmaceuticals upper circuit came as buying interest met the exchange-defined price band. At the time of writing the stock was locked at its upper circuit level, which makes the session worth noting for short-term market participants.

Table of Contents

Toggle
  • Key Takeaways
  • Key Market Data
  • Price Action and Trading Activity
  • Why Balaxi Pharmaceuticals Ltd. Hit Upper Circuit
  • What the Balaxi Pharmaceuticals Upper Circuit Means
  • Balaxi Pharmaceuticals Ltd. Fundamentals and Valuation
  • Peer and Sector Context
  • Technical Snapshot
  • What Readers Should Know
  • Frequently Asked Questions
    • Why did Balaxi Pharmaceuticals Ltd. hit upper circuit on 18 November 2026?
    • What was BALAXI share price on 18 November 2026?
    • What was the upper circuit price for BALAXI?
    • What is Balaxi Pharmaceuticals Ltd.’s market cap and PE ratio?
    • Which exchange and data source were used?
    • Does hitting an upper circuit mean Balaxi Pharmaceuticals Ltd. is a buy or a sell?
    • Can you buy or sell Balaxi Pharmaceuticals Ltd. shares when the stock is at the upper circuit?
    • What happens the next trading session after an upper circuit?
    • What is the upper circuit limit set at for Indian stocks?

Key Takeaways

  • Balaxi Pharmaceuticals Ltd. (BALAXI) hit the upper circuit on NSE at Rs 31.76 on 18 November 2026.
  • The session move was +19.98% against a previous close of Rs 26.47.
  • Market capitalisation stood at Rs 146.13 crore with a PE ratio of 43.43.
  • No official company announcement or verified catalyst was confirmed at the time of writing.
  • A price band is an exchange trading rule, not a view on the company or a recommendation.

Key Market Data

Metric Value
Stock Balaxi Pharmaceuticals Ltd.
Current Price / LTP Rs 31.76
Day Move 19.98%
Previous Close Rs 26.47
Day Open Rs 30
Day High Rs 31.76
Day Low Rs 27.8
Upper Circuit Price Rs 31.76
Upper Circuit Limit Rs 31.76
Market Cap Rs 146.13 crore
Selected Exchange NSE
PE Ratio 43.43

All figures above are as of 18 November 2026, sourced from Univest market data for the NSE listing. Only fields present in the source for this session are shown.

Price Action and Trading Activity

Balaxi Pharmaceuticals Ltd. opened at Rs 30 on NSE, compared with a previous close of Rs 26.47. During the session, the stock traded between Rs 27.8 and Rs 31.76 before touching the upper circuit price of Rs 31.76.

The absolute day change was Rs 5.29, while the percentage move was 19.98%. The event figures are kept to a single exchange so the numbers stay comparable.

The selected exchange matters because price bands, day range and previous-close values can differ across exchanges. This article uses NSE consistently for the event table and narrative. The stated upper circuit limit for the session was Rs 31.76, which is the level the price reached.

Why Balaxi Pharmaceuticals Ltd. Hit Upper Circuit

Balaxi Pharmaceuticals Ltd. hit the upper circuit after buying interest pushed the stock to its exchange-defined price band. No official company announcement or verified external catalyst was confirmed at the time of writing, so the move should be read primarily through price action and market sentiment.

Because no verified catalyst was available, this article does not attribute the move to earnings, corporate action, sector news, or market rumours. If a confirmed announcement becomes available later, it should be added as a separate update.

Within the session the stock reached the upper circuit level of Rs 31.76.

What the Balaxi Pharmaceuticals Upper Circuit Means

An upper circuit is the maximum price level a stock is allowed to reach during a trading session under the applicable exchange price band. For Balaxi Pharmaceuticals Ltd., the captured upper circuit price was Rs 31.76 on 18 November 2026.

The circuit mechanism is meant to slow extreme price movement and keep trading orderly. It is a market-structure fact, not a return forecast. In this article, the upper circuit explains what happened in the session and where the price band was reached.

Balaxi Pharmaceuticals Ltd. Fundamentals and Valuation

Available market data gives a fuller picture than price action alone. For Balaxi Pharmaceuticals Ltd., PE ratio was 43.43, PB ratio was 0.57, book value was Rs 46.04, EPS was 0.61, ROE was 0.59%, ROCE was 3.48%, dividend yield was 0% and debt-to-assets ratio was 0.22, on a market cap of Rs 146.13 crore. These are available financial indicators and should not be read as a buy, sell, or hold view.

For investors tracking upper circuit moves, these metrics help separate the price event from the broader financial profile. A sharp one-day move can attract attention, but valuation and return ratios still need to be reviewed separately.

Peer and Sector Context

Balaxi Pharmaceuticals Ltd. belongs to the Trading industry. The peer table below uses available companies from the same sector or industry to give broader valuation context.

Peer Company Market Cap PE PB ROE
Vintage Coffee & Beverages Ltd. Rs 2259.58 crore 28.69 4.08 17.91%
Confidence Petroleum India Ltd. Rs 2165.88 crore 11.84 1.41 7%
Creative Newtech Ltd. Rs 2095.73 crore 27.43 5.23 21.38%
Aayush Art And Bullion Ltd. Rs 2073.88 crore 262.79 34.12 13.89%
Prizor Viztech Ltd. Rs 1824.88 crore 87.14 26.86 38.29%

Several of these peers are far larger by market capitalisation than Balaxi Pharmaceuticals Ltd. Size differences change liquidity and cost of capital, so the table is sector context rather than a like-for-like ranking.

Balaxi Pharmaceuticals Ltd.’s PE ratio was 43.43, compared with an available peer PE average of 83.58, calculated from the 5 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.

Want to know more? Log in to Univest for more stock insights.

Technical Snapshot

The technical snapshot adds context: RSI was 70.86.

What Readers Should Know

The main confirmed fact is that Balaxi Pharmaceuticals Ltd. hit the upper circuit on NSE at Rs 31.76 on 18 November 2026, with a 19.98% day move.

The practical limitation after an upper-circuit session is execution. Buyers queue at the band and sellers step back, so the quoted price is not necessarily a price you can transact at. The other limitation is that no official catalyst was confirmed at the time of writing.

Readers should treat upper circuit events as market updates, not standalone investment conclusions. The price band shows strong near-term interest, but follow-up analysis should consider business fundamentals, valuation, liquidity, risk, and confirmed company disclosures.

Frequently Asked Questions

Why did Balaxi Pharmaceuticals Ltd. hit upper circuit on 18 November 2026?

The stock reached its upper price band after buying interest during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.

What was BALAXI share price on 18 November 2026?

The last traded price used in this article was Rs 31.76 on NSE. That price matched the upper circuit price captured for the event.

What was the upper circuit price for BALAXI?

The upper circuit price was Rs 31.76. The stated exchange upper circuit limit was Rs 31.76. The event numbers in this article are aligned to NSE.

What is Balaxi Pharmaceuticals Ltd.’s market cap and PE ratio?

Balaxi Pharmaceuticals Ltd.’s market cap was Rs 146.13 crore. PE ratio was 43.43.

Which exchange and data source were used?

The selected exchange was NSE. The article uses Univest market data available at the time of generation, captured on 18 November 2026.

Does hitting an upper circuit mean Balaxi Pharmaceuticals Ltd. is a buy or a sell?

No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.

Can you buy or sell Balaxi Pharmaceuticals Ltd. shares when the stock is at the upper circuit?

It is usually difficult. At the upper circuit, buy orders queue up while sellers step back, so there may be no counterparty at the quoted price. Orders can stay unfilled until the band opens up or sellers return.

What happens the next trading session after an upper circuit?

There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.

What is the upper circuit limit set at for Indian stocks?

Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For Balaxi Pharmaceuticals Ltd. the stated limit was Rs 31.76. For this session, Balaxi Pharmaceuticals Ltd. moved 19.98%.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply